drugset / Trial / NCT01003431

A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)

NCT01003431

Phase 3 Withdrawn Merck Sharp & Dohme LLC
RandomizedParallel-groupOpen-labelPrevention

Summary

This study will evaluate the immunogenicity and safety of the pertussis component of DTwP (whole-cell pertussis containing vaccine) when administered concomitantly with RotaTeq™ or Rotatrix™.

Timeline

Start
2009-12
Primary completion
2010-08
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adacel Vaccine 0.5 ml Intramuscular
Comparator Rotarix Vaccine 1 ml Oral
Comparator Rotarix Vaccine 2 ml Oral
Subject Tritanrix-HepB Vaccine 0.5 ml Intramuscular